| 1.77 0.08 (4.73%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.28 |
1-year : | 2.67 |
| Resists | First : | 1.96 |
Second : | 2.28 |
| Pivot price | 1.73  |
|||
| Supports | First : | 1.69 |
Second : | 1.52 |
| MAs | MA(5) : | 1.76 |
MA(20) : | 1.74 |
| MA(100) : | 1.89 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 68.5 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 2.59 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TLSA ] has closed below upper band by 35.8%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.8 - 1.81 | 1.81 - 1.82 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.76 - 1.77 | 1.77 - 1.78 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Tue, 02 Dec 2025
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Tue, 02 Dec 2025
Tiziana Life Sciences to Set Up a Publicly Listed Immunology-Focused Spinout Company, Centered on the IL-6 Market - marketscreener.com
Tue, 02 Dec 2025
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout - Investing.com India
Tue, 02 Dec 2025
Tiziana Life Sciences plans spinout of IL-6 antibody program - Proactive financial news
Tue, 02 Dec 2025
Tiziana Life Sciences (TLSA) Plans Spinout to Develop Anti-IL-6 Antibody - GuruFocus
Tue, 02 Dec 2025
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 119 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 46.1 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 1,440 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.8 % |
| Return on Equity (ttm) | -232.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -14.75 |
| PEG Ratio | 0 |
| Price to Book value | 22.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -24.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|